Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 104.44M P/E - EPS this Y -111.50% Ern Qtrly Grth -
Income 67.04M Forward P/E 2.25 EPS next Y 106.20% 50D Avg Chg 3.00%
Sales 140.14M PEG - EPS past 5Y - 200D Avg Chg 24.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -25.00%
Recommedations 1.50 Quick Ratio 5.90 Shares Outstanding 37.78M 52W Low Chg 149.00%
Insider Own 2.84% ROA 42.01% Shares Float 37.27M Beta 1.57
Inst Own 48.32% ROE 175.97% Shares Shorted/Prior 1.04M/0.95M Price 2.86
Gross Margin 88.85% Profit Margin 47.84% Avg. Volume 326,843 Target Price 7.88
Oper. Margin -397.88% Earnings Date May 8 Volume 77,925 Change -2.05%
About SCYNEXIS, Inc.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.

SCYNEXIS, Inc. News
04/30/24 SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
04/09/24 SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
03/28/24 SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
01/30/24 SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
01/29/24 SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
08:30 AM SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
11/30/23 Shareholders in SCYNEXIS (NASDAQ:SCYX) are in the red if they invested five years ago
11/27/23 11 Cheapest Stocks With Biggest Upside
11/13/23 SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update
10/24/23 SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)
10/16/23 SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece
09/27/23 SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance
09/27/23 Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?
09/25/23 UPDATE 4-Scynexis to recall GSK-partnered antifungal on cross contamination risk
09/20/23 PTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?
09/12/23 SCYNEXIS, Inc.'s (NASDAQ:SCYX) Stock Is Going Strong: Have Financials A Role To Play?
09/04/23 SCYNEXIS (SCYX) Skyrockets 134% Year to Date: Here's Why
08/28/23 Want to Get Rich? 3 Game-Changing Penny Stocks to Buy Right Now
08/28/23 SCYNEXIS to Participate in September Investor Conferences
08/16/23 Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues
SCYX Chatroom

User Image ViktorSinclair Posted - 8 hours ago

$SCYX This is what scyx shareholders feel like...

User Image Essential Posted - 2 days ago

$SCYX This good to buy and hold.

User Image str8bite Posted - 3 days ago

$SCYX NEED NEWS IN WORST WAY! Cmon!

User Image Pommy1 Posted - 4 days ago

$SCYX ur dream will come true its almost gona happen

User Image ViktorSinclair Posted - 4 days ago

$SCYX i had an SCYX dream last night…(really!) the world was having a horrible fungus breakout and there was a lot of panic. it was worse than covid and people were dying and there was not much that could help them. 247 was getting close showed lots of promise but not approved yet. confidence was high that they could fight the fungus successfully. the government got behind scyx and accelerated 247’s use. stock went to 200 in a week. it was the only alternative. lots to chatter on reddit aka gamestop, when it cured the first few patients that were in their death bed, and stock soon went to 400 in 2 months and the company did a 20 for 1 split. taking it to 20. GSK was prohibited from buying 247 by our government and insisted that it remain in US hands. offers started coming in and the stock got 35 and then my alarm went off and i woke up. sweet dreams 🛌

User Image Stock_Titan Posted - 04/30/24

$SCYX SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID) https://www.stocktitan.net/news/SCYX/scynexis-presented-preclinical-data-on-second-generation-fungerp-scy-s8ri58u5n1jj.html

User Image ViktorSinclair Posted - 04/30/24

$SCYX

User Image pantarei Posted - 04/30/24

$SCYX ploff!

User Image Pommy1 Posted - 04/30/24

$SCYX data is very very promising.the s price is now waiting on it.will be big big jump from there

User Image pantarei Posted - 04/30/24

$SCYX FURI is officially COMPLETED. When do we get our data?? https://www.clinicaltrials.gov/study/NCT03059992?term=scynexis&page=2&rank=16

User Image LemuelPitkin Posted - 04/29/24

$SCYX Excellent day corresponding to commencement of EU Microbiology conference presentations. But never forget the tactic: -> buy the rumour, sell the news. That last part is the concern. I look forward to *real* progress over the months to come. Buy and Hold.

User Image str8bite Posted - 04/29/24

$SCYX Why is this up?

User Image Invest2live Posted - 04/29/24

$SCYX 21% already; congrats 🎉🎈🎊 Follow for more research based stock alerts

User Image Pommy1 Posted - 04/29/24

$SCYX wt happened in europe

User Image RenaissanceTrading Posted - 04/29/24

$SCYX Entered at $1.75. Just starting!

User Image Essential Posted - 04/29/24

$SCYX Increasing the amount of cash.

User Image cklee88 Posted - 04/29/24

$SCYX pr soon?

User Image ViktorSinclair Posted - 04/29/24

$SCYX

User Image Westcoastcrippler Posted - 04/27/24

$SCYX Anyone else think that they can help the old guys prostates with this? I have been hearing a lot of the problems are due to fungal issue. How big is that market?

User Image str8bite Posted - 04/27/24

$SCYX Isnt data being presented today?

User Image Pommy1 Posted - 04/26/24

$SCYX this time it looks some real stuff happening no bs lol.finally in action

User Image Westcoastcrippler Posted - 04/26/24

$SCYX 14k buy premarket is a nice start.

User Image pjinvestmentco Posted - 04/25/24

$SCYX from today's filing for the annual meeting... "In response to the hold on clinical studies of ibrexafungerp by the FDA due to possible beta-lactam cross contamination, we have entered into certain new manufacturing agreements with third-party contract manufacturers to begin producing new batches of ibrexafungerp which we believe will allow us to lift the clinical hold and restart our impacted clinical studies, the Phase 3 MARIO study and a Phase 1 lactation study."

User Image Pommy1 Posted - 04/25/24

$SCYX hmmm voting time is comming hmmm.

User Image LemuelPitkin Posted - 04/25/24

$SCYX Annual Meeting of shareholders: June 19, 2024. My preference as of today: Vote for the current board, CEO, Management. Why? The stock price is an illusion. It is not what matters because the real value of SCYX is only going to be realized when Ibrexafungerp is fully approved and on the market and SCY-247 follows in likewise manner. And who has the positive track record to get this done? The current board and management. So don't be little girls and whine about the current stonk price. Fuk the current stonk price, it says NOTHING. https://ir.scynexis.com/sec-filings

User Image Pommy1 Posted - 04/25/24

$SCYX after the conference they will get buyer from europe n they will sell the co.tyey been doing too many confrence in europe.so hold on to ur stocks n keep buying more.after conference we all be rich

User Image pantarei Posted - 04/25/24

$SCYX DEAD Company

User Image ViktorSinclair Posted - 04/25/24

$SCYX all time low on deck. david, do something!

User Image Justfactsplease Posted - 04/25/24

$SCYX we have the same people clocking in and writing FUD in the forum-- but doing it less... do your own research an see the entities with millions of shares and having to file 13g w/SEC because they own 5% of SCYX and the GSK deal and upcoming FDA approvals.

User Image pantarei Posted - 04/24/24

$SCYX proooottt

Analyst Ratings
Cantor Fitzgerald Overweight Apr 1, 24
Cantor Fitzgerald Overweight Aug 15, 23
Guggenheim Buy Apr 3, 23
Ladenburg Thalmann Buy Apr 3, 23
Guggenheim Buy Mar 1, 23
HC Wainwright & Co. Buy May 13, 22
HC Wainwright & Co. Buy Mar 31, 22
Aegis Capital Buy Jun 7, 21
Aegis Capital Buy Apr 12, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Taglietti Marco Chief Executive Offi.. Chief Executive Officer Apr 26 Buy 3.00 75,000 225,000 272,068 04/28/22
Sukenick Scott General Counsel General Counsel Apr 26 Buy 3.00 3,500 10,500 53,499 04/28/22
- - - Jan 26 Sell 7.98 599,000 4,780,020 1,800,000 01/26/21